导师风采
李春香
个人信息
Personal Information
- 性别：女
- 导师类型：博士生导师
- 职称：教授
- 该职称任职时间：20150901
联系方式
Contact Information
- 所属院系：肿瘤医院
- 所属专业：肿瘤学
- 邮箱 : lichunxiang@cicams.ac.cn
- 工作电话 : 010-67781331
个人简介
Personal Profile
李春香，女，蒙古族，1979年4月生，中共党员，中国医学科学院肿瘤医院教授，博士研究生导师。博士毕业于哈尔滨医科大学生物化学与分子生物学专业，从事肿瘤遗传与分子标记物研究20年。主要从事肺癌和食管癌的分子标志物和临床转化研究。近年来，共发表SCI学术论文40余篇，主持国家自然基金面上项目1项、国家自然基金青年项目1项、国家重点研发计划项目2项、国家级博士后课题1项、省部级课题2项。 工作经历： 2004.7 ~ 2007.7，哈尔滨医科大学，基础医学院，医学遗传学教研室，助教 2007.7 ~ 2010.7，哈尔滨医科大学，基础医学院，医学遗传学教研室，讲师 2010.7 ~ 2015.9，哈尔滨医科大学，基础医学院，医学遗传学教研室，副教授 2015.9 ~ 2018.2，哈尔滨医科大学，基础医学院，医学遗传学教研室，教授 2018.4 ~ 今，国家癌症中心/中国医学科学院肿瘤医院，胸外科实验室，教授
团队简介
Team Profile
中国医学科学院肿瘤医院胸外科创建于1958年，是我国第一个胸部肿瘤外科，现为国家重点临床专科，在复旦大学医院管理研究所发布的“中国医院专科声誉排行榜”上连续12年位列全国胸外科综合排行榜第一名，年手术量达5000例，其中胸部肿瘤数量居全国之首。 中国医学科学院肿瘤医院胸外科实验室由我国胸部肿瘤领军专家赫捷院士一手创办，具有20年的研究历史，现有院士1名（课题组PI赫捷院士），研究员1名，副研究员2名，工作人员6名，在读博士研究生及博士后流动人员30余名，北京协和医学院临床医学（八年制）工作人员轮转进行课题研究10余名。实验室具有先进完善的分子生物学实验、生物信息学技术平台及国内最大的肺癌标本组织库。
- 研究方向Research Directions
肺癌和食管癌的分子标志物研究
- 在校研究生Current Graduate Students
硕士研究生 2 名，博士研究生 1 名
- 科研项目Research Projects
| # | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
|---|---|---|---|---|---|
| 1 | AJUBA截短突变的功能影响与食管鳞癌癌前病变发生机制研究 | 2019-12-31 —— | 55.0 | ||
| 2 | 多原发肺癌中胚系突变Pim-1的功能及作用机制研究 | 2020-01-01 —— | 55.0 | ||
| 3 | 基于跨尺度多模态生物医学大数据的肿瘤智能诊疗共性关键技术研究 | 2022-01-01 —— | 4200.0 | ||
| 4 | 重点疾病防治集成性研究 | 2021-10-01 —— | 4480.0 |
- 发表论文Papers
| # | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
|---|---|---|---|---|
| 1 | TGF-β signaling in health, disease, and therapeutics | Signal Transduct Target Ther | 2024-03 | 共同通讯 |
| 2 | Genomic characteristics and immune landscape of super multiple primary lung cancer | EBioMedicine | 2024-03 | 共同通讯 |
| 3 | CXXC finger protein 1 (CFP1) bridges the reshaping of genomic H3K4me3 signature to the advancement of lung adenocarcinoma | Signal Transduct Target Ther | 2023-09 | 共同通讯 |
| 4 | KLF12 overcomes anti-PD-1 resistance byreducing galectin-1 in cancer cells | J Immunother Cancer | 2023-08 | 共同通讯 |
| 5 | H3K4 trimethylation regulates cancer immunity: a promising therapeutic target in combination with immunotherapy | J Immunother Cancer | 2023-08 | 共同通讯 |
| 6 | BATF reprograms the tumor immune status | Med | 2023-01 | 共同通讯 |
| 7 | H3K4me3-related lncRNAs signature and comprehensive analysis of H3K4me3 regulating tumor immunity in lung adenocarcinoma | Respir Res | 2023-05 | 共同通讯 |
| 8 | Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis | Cancer Gene Ther | 2023-03 | 共同通讯 |
| 9 | Multiple primary lung cancer: Updates of clinical management and genomic features | Front Oncol | 2023-02 | 共同通讯 |
| 10 | CCL20 promotes lung adenocarcinoma progression by driving epithelial-mesenchymal transition | Int J Biol Sci | 2022-06 | 共同通讯 |
| 11 | Establishment and Validation of an Interferon-Stimulated Genes (ISGs) Prognostic Signature in Pan-cancer Patients: A Multicenter, Real-world Study | Int J Biol Sci | 2022-05 | 共同通讯 |
| 12 | Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy | Front Cell Dev Biol | 2022-09 | 共同通讯 |
| 13 | The RNA-binding protein PCBP1 represses lung adenocarcinoma progression by stabilizing DKK1 mRNA and subsequently downregulating β-catenin | J Transl Med | 2022-07 | 共同通讯 |
| 14 | Lipid metabolism-related lncRNA SLC25A21-AS1 promotes the progression of oesophageal squamous cell carcinoma by regulating the NPM1/c-Myc axis and SLC25A21 expression | Clin Transl Med | 2022-06 | 共同一作 |
| 15 | PSC subtyping based on TTF-1 and p40 expression reveals distinct molecular characteristics and therapeutic strategies | Int J Cancer | 2022-09 | 共同通讯 |
| 16 | Transmembrane Protein-Based Risk Model and H3K4me3 Modification Characteristics in Lung Adenocarcinoma | Front Oncol | 2022-03 | 共同通讯 |
| 17 | ERAP2 Is Associated With Immune Infiltration and Predicts Favorable Prognosis in SqCLC | Front Immunol | 2021-12 | 共同通讯 |
| 18 | Prognostic value of immune-related genes and comparative analysis of immune cell infiltration in lung adenocarcinoma: sex differences | Biol Sex Differ | 2021-12 | 共同通讯 |
| 19 | A Multi-Center Validated Subtyping Model of Esophageal Cancer Based on Three Metabolism-Related Genes | Front Oncol | 2021-10 | 共同通讯 |
| 20 | H3K36 trimethylation-mediated biological functions in cancer | Clin Epigenetics | 2021-10 | 共同通讯 |
| 21 | Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma | Cancer Immunol Immunother | 2021-12 | 共同通讯 |
| 22 | A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis | Front Immunol | 2021-06 | 共同通讯 |
| 23 | LncRNA EGOT/miR-211-5p Affected Radiosensitivity of Rectal Cancer by Competitively Regulating ErbB4 | Onco Targets Ther | 2021-04 | 共同一作 |
| 24 | Presentation of EGFR mutations in 162 family probands with multiple primary lung cancer | Transl Lung Cancer Res | 2021-04 | 共同一作 |
| 25 | A Novel Immune-Related Prognostic Model for Response to Immunotherapy and Survival in Patients With Lung Adenocarcinoma | Front Cell Dev Biol | 2021-03 | 共同通讯 |
| 26 | The therapeutic significance of the novel photodynamic material TPE-IQ-2O in tumors | Aging (Albany NY) | 2020-12 | 共同通讯 |
| 27 | Immune profile of the tumor microenvironment and the identification of a four-gene signature for lung adenocarcinoma | Aging (Albany NY) | 2020-12 | 共同通讯 |
| 28 | The Prognostic Significance of Metabolic Syndrome and aRelated Six-lncRNA Signature in Esophageal Squamous Cell Carcinoma | Front Oncol | 2020-02 | 共同通讯 |
| 29 | Leptin Overexpression as a Poor Prognostic Factor for Colorectal Cancer | Biomed Res Int | 2020-06 | 共同一作 |
- 科研获奖Research Awards
无
- 研究成果Research Findings
| # | 成果类型 | 项目/专利/新品种名称 |
|---|---|---|
| 1 | 作为主创人员获得授权的发明专利和新品种 | 用于预测直肠癌局部切除手术后复发风险的组合物、微阵列和计算机系统 |
| 2 | 作为主创人员获得授权的发明专利和新品种 | LncRNA SLC25A21-AS1在作为食管癌标志物中的应用 |